Gilenya Fails to Ease Rett Symptoms in Phase 1/2 Trial
Despite being safe, one year of treatment with Gilenya (fingolimod) in young girls with Rett syndrome failed to ease such disease symptoms as lack of communication, motor impairments, and apraxia, or the inability to perform movements previously learned, a small Phase 1/2 trial showed. Moreover, the findings from the…